Royalty Pharma PLC

NAS:RPRXHealthcareNASDAQ:NBISTOXX:EDD24BP

$60.09−1.43%LiveIn session · ≈ AED 220.68 · Market cap $34.55B · Next earnings Wed 4 Nov

RPRX · Income statement · TradingHolo

USD billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM	YoY
Revenue	2.1	2.3	2.2	2.4	2.3	2.4	2.5	+6.6%
Cost of revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Gross profit	2.1	2.3	2.2	2.4	2.3	2.4	2.5	+6.4%
Research & development	0.0	0.2	0.2	0.1	0.0	0.5	0.2	−47.2%
Selling, general & administrative	0.2	0.2	0.2	0.2	0.2	0.6	—	—
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Operating expenses	0.5	0.9	1.9	0.9	1.0	0.8	1.0	+16.5%
Operating income	1.6	1.4	0.3	1.5	1.3	1.6	1.6	+1.4%
Interest expense	0.2	0.2	0.2	0.2	0.2	0.3	0.4	+17.4%
Interest income	0.0	0.1	0.1	0.1	0.0	0.0	—	—
Other income / expense	0.1	(0.2)	(0.1)	0.2	0.0	(0.2)	—	—
Pre-tax income	1.7	1.2	0.2	1.7	1.3	1.3	1.3	+1.9%
Income tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—
Net income	1.0	0.6	0.0	1.1	0.9	0.8	0.8	+5.8%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—	—
EPS, basic (per share)	1.28	1.49	0.10	3.41	1.92	2.33	1.89	−18.9%
EPS, diluted (per share)	1.28	1.49	0.10	2.53	1.91	1.80	1.74	−3.4%
EBITDA	1.9	1.4	0.4	1.9	1.6	1.6	1.5	−7.3%
Depreciation & amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0	+28.2%
Weighted average shares (shares)	388,135,000	414,794,000	437,963,000	447,601,000	445,985,000	431,887,000	—	—
Weighted average diluted shares (shares)	388,135,000	414,802,000	564,931,250	602,900,000	594,000,000	559,611,000	—	—
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	−0.2 pts
Operating margin	75.2%	62.5%	13.7%	63.4%	57.1%	65.6%	62.3%	−3.2 pts
Net margin	45.9%	27.1%	1.9%	48.2%	37.9%	32.4%	32.1%	−0.3 pts

USD billionsUpdated Wed 5 Aug ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

TTM ends 2026-06-30 and uses four consecutive reported quarters.